Nivolumab

(asked on 18th January 2016) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what information his Department holds on the effects of nivolumab on one year survival rates for lung cancer.


Answered by
George Freeman Portrait
George Freeman
This question was answered on 29th January 2016

Nivolumab is currently marketed in the European Union under the brand name Opdivo.


The data available when Opdivo was licensed in 2015 indicated overall survival among patients given the product was around nine months, whereas among the patients given docetaxel, another cancer medicine, it was six months.

Reticulating Splines